We performed a systematic review and meta-analysis of randomised controlled trials (RCTs)
conducted from January 2005 to June 2021 to update the evidence of Botulinum toxin A …

Abstract Background and Objective Botulinum toxin type A (BTX‐A) is a recently developed
treatment for the management of peripheral neuropathic pain. The objective of this study …

Background: The aim of this paper is to provide a systematic review of the literature
regarding the clinical use of botulinum toxin (BTX) to treat various orofacial neuropathic pain …

Background This study aimed to predict the quality of life (QOL) in patients with Painful
Diabetic Neuropathy (PDN) based on pain severity, pain catastrophizing, pain acceptance …

Background and aims Botulinum toxin type A (BTX-A) have been recently administered to
improve Diabetic neuropathies; however, the efficacy of this treatment for relieving pain in …

Clinical management of sacroiliac disease has proven challenging from both diagnostic and
therapeutic perspectives. Although it is widely regarded as a common source of low back …

Botulinum neurotoxins (BoNTs) are a family of neurotoxins produced by Clostridia and other
bacteria that induce botulism. BoNTs are internalized into nerve terminals at the site of …

Although botulinum toxin (BoNT) has been suggested as a treatment to counter neuropathic
pain, no previous systematic reviews investigated the multidimensional effects of BoNT on …

Background: The present study aimed to evaluate the reasons and determinants of BoNT-A
discontinuation in patients with stroke, multiple sclerosis, spinal cord injury, and traumatic …

The rising prevalence of diabetes mellitus (DM) leads on to an increase in chronic diabetic
complications. Diabetic peripheral neuropathies (DPNs) are common chronic complications …